TY - JOUR
T1 - Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53
AU - Morita, A.
AU - Zhu, J.
AU - Suzuki, N.
AU - Enomoto, A.
AU - Matsumoto, Y.
AU - Tomita, M.
AU - Suzuki, T.
AU - Ohtomo, K.
AU - Hosoi, Y.
N1 - Funding Information:
We thank all the members of our laboratory for their help and encouragement. We also thank Dr. T Shibue and Professor T Taniguchi (University of Tokyo) for their kind gift of the Ba/F3 cells, and Dr. M Enari (National Cancer Center, Tokyo, Japan) for various suggestions and instructions, especially regarding the ChIP assays. This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture, the Ministry of Health and Welfare of Japan.
PY - 2006/3
Y1 - 2006/3
N2 - We previously reported that p42/SETβ is a substrate for caspase-7 in irradiated MOLT-4 cells, and that treating the cells with sodium orthovanadate (vanadate) inhibits p42/SETβ's caspase-mediated cleavage. Here, we initially found that the inhibitory effect of vanadate was due to the suppression of caspase activation but not of caspase activity. Further investigations revealed that vanadate suppressed upstream of apoptotic events, such as the loss of mitochondrial membrane potential, the conformational change of Bax, and p53 transactivation, although the accumulation, total phosphorylation, and phosphorylation of six individual sites of p53 were not affected. Importantly, vanadate suppressed p53-dependent apoptosis, but not p53-independent apoptosis. Finally, gel-shift and chromatin immunoprecipitation assays conclusively demonstrated that vanadate inhibits the DNA-binding activity of p53. Vanadate is conventionally used as an inhibitor of protein tyrosine phosphatases (PTPs); however, we recommend that the influence of vanadate not only on PTPs but also on p53 be considered before using it.
AB - We previously reported that p42/SETβ is a substrate for caspase-7 in irradiated MOLT-4 cells, and that treating the cells with sodium orthovanadate (vanadate) inhibits p42/SETβ's caspase-mediated cleavage. Here, we initially found that the inhibitory effect of vanadate was due to the suppression of caspase activation but not of caspase activity. Further investigations revealed that vanadate suppressed upstream of apoptotic events, such as the loss of mitochondrial membrane potential, the conformational change of Bax, and p53 transactivation, although the accumulation, total phosphorylation, and phosphorylation of six individual sites of p53 were not affected. Importantly, vanadate suppressed p53-dependent apoptosis, but not p53-independent apoptosis. Finally, gel-shift and chromatin immunoprecipitation assays conclusively demonstrated that vanadate inhibits the DNA-binding activity of p53. Vanadate is conventionally used as an inhibitor of protein tyrosine phosphatases (PTPs); however, we recommend that the influence of vanadate not only on PTPs but also on p53 be considered before using it.
KW - Apoptosis
KW - Caspase
KW - DNA damage
KW - Sodium orthovanadate
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=33645163703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645163703&partnerID=8YFLogxK
U2 - 10.1038/sj.cdd.4401768
DO - 10.1038/sj.cdd.4401768
M3 - Article
C2 - 16138109
AN - SCOPUS:33645163703
SN - 1350-9047
VL - 13
SP - 499
EP - 511
JO - Cell Death and Differentiation
JF - Cell Death and Differentiation
IS - 3
ER -